Sale of Ebopiprant royalty and milestone license to XOMA includes upfront payment of $15 million and future milestone payments of up to $98 million The sale proceeds are expected to enable ObsEva to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback